Business highlights
2018: Incorporation of Cleara Biotech B.V. through a joint effort by Apollo Health Ventures and dr. Peter de Keizer
2019: Cleara becomes the main industrial partner of the ZonMw/Health~Holland Public Private Initiative Voila/SMARTage
2020: Addition of Cambrian Bioventures to Cleara’s investment syndicate to pursue research and optimization phase
2021-22: Establishment of CL04177 and CL04183 as lead candidates
2022: Successful nomination of two lead candidates, CL04177 and CL04183 leads to a sizeable investment by Apollo VC, Curie Capital, ROM Utrecht, LongevityTech.Fund and ISTAR Biotech B.V.
2022: Cleara becomes the main industrial partner of the ZonMw/Health~Holland Public Private Initiative TASCFORCE together with independent groups at the UMC Utrecht (Netherlands) to investigate to potential of CL04183 in (colon) cancer
2023: Successful nomination of CL04183 as Development Candidate
2023: Advice by the EMA/MEB on how preclinical development and GLP-Tox studies should look like for CL04183
2023+2024: Nomination of CL04183 as Development Candidate leads Cleara to pursue GLP-Tox studies and GMP-quality CMC, supported by a sizeable investment by existing investors, expanded by Korify Capital / Infinitas.
Company-wide due diligence by the (public) Dutch Governmental Agency RVO leads to full endorsement of Cleara’s program for preclinical development of CL04183, matched by financial support.
2025: Completion of GLP-Tox studies in rats and non-human primates.
Completion of GMP-grade Drug Substance work and progress into Drug Product phase for clinical trial submission
Corporate development
2018: Execution of a principal long-term collaboration and license agreement executed with UMC Utrecht; Netherlands
Execution of supporting collaboration and license agreements with UMC Groningen (dr. Marco Demaria) and MU Graz; Austria (Prof. Tobias Madl).
2019: Nomination of Peter de Keizer, PhD as sole Managing Director
2019: Recruitment of Michael Teifel, PhD as senior Preclinical Development expert
2019: Agreement with one of the top accountancy firms for financial diligence
2022: Recruitment of Angelos Stergiou, MD as Chairman of the Board
2022: Promotion of Esmée Bouma to Laboratory Manager
2023: Recruitment of Nick Sarlis, MD, PhD as Chief Medical Officer
2023: Recruitment of Gerd Hummer as preclinical regulation expert
2023: Promotion of Marjolein Baar, PhD as Head of Research Management
2023: Recruitment of Laurens van Pinxteren as Head of Technical Operations
2024: Recruitment of Jörg Herbst, Dipl. Chem PhD, ERT, DABT as Project Manager preclinical Research
2025: Recruitment of Frank Niemöller as Head of Finance